Details for Patent: 8,623,409

Which drugs does patent 8,623,409 protect, and when does it expire?

Patent 8,623,409 protects NEXICLON XR and is included in one NDA.

Summary for Patent: 8,623,409

Title:	Clonidine formulation
Abstract:	An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.
Inventor(s):	Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee:	Tris Pharma Inc. (Monmouth Junction, NJ)
Application Number:	12/908,796
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Dosage form;

Drugs Protected by US Patent 8,623,409

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Athena	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-001	Dec 3, 2009		RX	No	No			Y
Athena	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-002	Dec 3, 2009		DISCN	No	No			Y